Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

Abstract

Mutations; Relapse; T-cell acute lymphoblastic leukemia

Mutacions; Recaiguda; Leucèmia limfoblàstica aguda de cèl·lules T

Mutaciones; Recaída; Leucemia linfoblástica aguda de células T

Relapse is the main cause of treatment failure in T-cell acute lymphoblastic leukemia (T-ALL). Despite this, data from adult T-ALL patients treated with specific chemotherapeutic regimens that examine predictive markers and describe relapse mechanisms are scarce. In this study, we studied 74 paired diagnosis-relapse samples from 37 patients homogeneously treated with three consecutive measurable residual disease-oriented trials to identify genetic determinants involved in relapse in adult T-ALL. Analysis of single-nucleotide variants and copy number alterations consistently found N/KRAS mutations (20% relapsed cases) at diagnosis and at relapse (resistance profile). N/KRAS mut patients frequently relapse early during consolidation treatment. Relapse-specific mutations in NT5C2, NR3C1, SMARCA4, and TP53 (40% relapse cases) were not detected at diagnosis by conventional molecular techniques (relapse profile). However, single-cell-based analysis revealed a very minor clone containing the NT5C2(p.R367Q) variant at diagnosis. Patients with the NT5C2(p.R367Q) variant mostly relapse later during maintenance treatment. Tracking the NT5C2 variant by digital PCR confirm the expansion of the NT5C2 clone at maintenance treatment. Overall, our exploratory analysis suggests a role for these genetic events, most of which have already been described in pediatric cases, driving resistance associated to specific chemotherapeutic agents, contributing to the relapse of a high proportion of adult T-ALL patients (60%).

This project was supported by the AECC (GC16173697BIGA), ISCIII (PI19/01828, PI19/01183, and PI22/01880), co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future,” and CERCA/Generalitat de Catalunya SGR 2021 (ref 00560). Thaysa Lopes was supported by the Leukemia Stiftung (DJCLS 08R/2022).